

Corrections/Changes to FDA Clinical Briefing Document December 10, 2002

1. Appendix 4.1 was inadvertently not provided with the Briefing Document. This is now provided.
2. Page 4, section 2.1, line 7. A fourth study in the BLA without a finalized CSR, i.e. the Pediatric HIV study, was also removed from the final database.
3. Page 5, Table 2.1.
The number of children in 1-2 year old age group category has been corrected from “256” to “756” and the total row from “1541” to “2041.” Additionally, the footnote has been corrected to show that the asthma subjects were enrolled in Study **AV010**, not AV012 as written previously.

Table 2.1b. Total Number of Doses of FluMist and Placebo Administered (by Age Group) in Trials with Completed Clinical Study Reports Submitted in the BLA

Age Category	Doses of FluMist ^a						Doses of Placebo Total
	First	Second	Third	Fourth	Fifth	Total	
1-2 years	1285	756				2041	730
2-4 years	4678	2889	475	188	1	8231	2593
5-8 years	4418	2643	365	367	1	7794	1970
9-17 years	5903	1028				6931	1371
18-29 years	1081	29				1110	458
30-49 years	2241	9				2250	1037
50-64 years	511					511	209
65 years and up	111					111	101
Total All Studies^b	20228	7354	840	555	2	28979	8469

^aThe fourth and fifth doses represent vaccination for a third annual season.

^bIncludes 171 children in Studies AV002 and AV002-2 who received 10⁴, 10⁵, and 10⁶ TCID₅₀ dosages rather than 10⁷ TCID₅₀, 28 HIV-infected adults in Study DMID #98-005, and 24 children 9-17 years with moderate to severe asthma in **AV010**.

Table adapted from MedImmune, November 2002.

4. Page 7, last paragraph. This should be revised to state that, “MAEs were analyzed individually **and** within four pre-specified grouped diagnoses.”
5. Page 8, paragraph 2. The sentence should be revised, “Results were presented separately for clinic, ED, hospitalizations **and all settings combined**.”

6. Page 14, Table 2.2.1h contained a typographical error (37569) in the FluMist column, which has been corrected to “8/3769.”

Table 2.2.1h. Abdominal Pain Events with Significantly Increased or Decreased Relative Risk by Age Group and Setting

Age	Setting	Dose	Number of Participants* with Events/Number in Age Group		Binomial Risk (90% CI)
			FluMist n/N	Placebo n/N	
1-17 years	ED	Both	14/6473	1/3216	6.94 (1.52, 73.81)
9-17 years	ED	1	7/2704	0/1347	-- (1.28, NA)
1 – 8 years	Clinic	1	8/3769	11/1869	0.36 (0.16, 0.78)
1 – 8 years	All	1	10/3769	12/1869	0.41 (0.20, 0.85)

*One FluMist subject reported two abdominal pain events.

NA = not available due to 0 events in placebo subjects

Table generated by CBER

7. Page 24, paragraph 2, last sentence. This sentence should be revised, “With this method, the **probability** that a FluMist vaccinee will transmit vaccine virus to a placebo subject was estimated, in contrast to assessing the number of placebo subjects infected, as planned in the original design.”
8. Page 43, Concomitant immunizations, 2nd paragraph. The sentence should be revised, “The sponsor has initiated a trial, AV018, evaluating concomitant use of FluMist with MMR? and VARIVAX? in **12-15** month old children.”
9. Page 50, 5th paragraph. The last sentence should be revised, “The criteria for performing viral cultures, prior to the influenza season were 2 signs or symptoms in category “a” OR ≥ 1 sign or symptom **from category “a”** plus ≥ 1 from category “b,” as follows:
10. Page 58, the second to last paragraph. The analysis for site-specific influenza outbreak periods was defined prior to un-blinding. The paragraph should be revised as follows, “Influenza outbreaks were identified in the community using a pre-defined algorithm. All of the illness-associated endpoints were analyzed during the entire study period (11/1/97 – 3/31/98), the site-specific influenza outbreak periods, and a pooled, 14-week outbreak period 12/14/97-3/21/98.”